Sfondo Header
L'angolo del dottorino
Search the site... Advanced search
✖

Causes of pulmonary hypertension:
why pressure in the lungs increases

Pulmonary hypertension is not a single disease. It is a hemodynamic condition characterized by increased pressure in the pulmonary circulation and may result from very different mechanisms: diseases of the small pulmonary arteries, disorders of the left heart, lung diseases and impaired oxygenation, chronic pulmonary arterial obstructions, or systemic and multifactorial conditions.
This is why identifying the cause is essential. Two people with elevated pulmonary pressure may have entirely different diseases and require different treatments.

The causes are divided into five main categories:


Pulmonary hypertension is therefore classified according to the predominant mechanism and the underlying disease, rather than solely according to how high a value measured by echocardiography or catheterization may be.

Why pressure in the pulmonary circulation can increase

The right ventricle pumps blood to the lungs through a circulation that normally offers very low resistance. Pressure may rise when pulmonary arteries become narrower or undergo remodeling, when part of the vascular bed becomes obstructed, when lung disease or hypoxia causes vasoconstriction and loss of functional vessels, or when elevated downstream pressure in the left heart is transmitted backward toward the lungs.
These mechanisms are not equivalent. The term "pulmonary hypertension" therefore describes a common hemodynamic finding but does not automatically identify its cause.

In some people, one dominant mechanism is clearly identifiable; in others, several factors may coexist. A patient with COPD, for example, may also have left heart disease or a history of pulmonary embolism. In systemic sclerosis, pulmonary vascular involvement, interstitial lung disease and cardiac dysfunction may also coexist. In complex cases, it is necessary to establish which mechanism contributes most to the clinical presentation.

Pulmonary arterial hypertension: when the problem mainly affects the small pulmonary vessels

Among the conditions in group 1 is pulmonary arterial hypertension, often abbreviated as PAH (or IAP in Italian). In this form, the main problem involves the pulmonary arterial circulation and is associated with increased pulmonary vascular resistance. Diagnosis requires specific hemodynamic criteria measured by right heart catheterization and exclusion of other, more likely causes.

PAH may be idiopathic, meaning that no identifiable cause is found, or heritable, when associated with predisposing genetic variants. There are also forms associated with certain medications or toxins, connective tissue diseases such as systemic sclerosis, HIV infection, portal hypertension, certain congenital heart diseases and schistosomiasis.
Recognizing these settings is important because it may change the investigations required, family assessment, treatment and prognosis.

Group 1 also includes rare forms involving pulmonary veins or capillaries, such as pulmonary veno-occlusive disease. These conditions require particular expertise because they may behave differently from more common forms of PAH and have specific therapeutic implications.

Left heart diseases: a very common cause in adults

The group 2 includes pulmonary hypertension due to left heart disease. It is among the most common forms in clinical practice, particularly in adults and older people. It may occur in heart failure with reduced, mildly reduced or preserved ejection fraction, valvular heart disease and other conditions that increase pressure in the left atrium or left ventricle.
When left heart filling pressure is elevated, it is transmitted backward to the pulmonary veins and capillaries. Over time, increased pulmonary vascular resistance may also develop in some patients.

Distinguishing these forms from true PAH is essential because medications developed for pulmonary arterial hypertension must not be used automatically in patients with left heart disease. The specialist page on pulmonary hypertension due to left heart disease explores this category in greater detail.

Lung diseases, hypoxia and respiratory disorders

The group 3 includes pulmonary hypertension associated with lung diseases and/or hypoxia. The most important settings include chronic obstructive pulmonary disease, emphysema, interstitial lung diseases and certain conditions characterized by chronically inadequate oxygenation.
Mechanisms may combine hypoxic vasoconstriction, loss or destruction of the pulmonary vascular bed, structural vascular changes and consequences of the underlying respiratory disease.

The severity of lung disease and that of pulmonary hypertension do not always progress in parallel. In some patients, the increase in vascular resistance is disproportionate to the apparent extent of respiratory damage and warrants more detailed specialist assessment. Forms in this group are discussed in the articles on pulmonary hypertension due to lung diseases and pulmonary hypertension due to hypoxia.

Chronic thromboembolism and multifactorial forms

The group 4 includes forms due to pulmonary arterial obstructions. The most important is chronic thromboembolic pulmonary hypertension, or CTEPH. After pulmonary embolism, thrombi resolve or become organized without causing CTEPH in the vast majority of people; in a minority, however, persistent fibrotic material may narrow or occlude branches of the pulmonary arterial tree. Small-vessel disease may accompany the mechanical component.
This diagnosis is particularly important because specific treatment options are available, including potentially curative procedures for selected patients.

The group 5 covers conditions in which increased pulmonary pressure may arise from complex, multiple or incompletely defined mechanisms. It includes certain hematologic, systemic and metabolic diseases, as well as other selected conditions. It is therefore not a category "without a cause": rather, the mechanism cannot readily be assigned to one of the first four groups. The dedicated specialist page discusses multifactorial pulmonary hypertension.

Determining the cause requires integrating the medical history, medications and exposures, echocardiography, respiratory function, imaging, ventilation/perfusion scintigraphy, laboratory investigations and, when indicated, right heart catheterization. Classification does more than name the disease: it determines which treatment may be beneficial and which therapies might instead be ineffective or inappropriate.

Frequently asked questions about the causes of pulmonary hypertension

What is the most common cause of pulmonary hypertension?
Forms associated with left heart disease are very common among adults. However, pulmonary hypertension comprises different groups, and the cause must be established in each patient because it determines treatment.

Can pulmonary hypertension be caused by lung disease?
Yes. COPD, interstitial lung diseases, certain conditions involving hypoxia and other respiratory disorders may be associated with pulmonary hypertension.

Can pulmonary embolism cause pulmonary hypertension?
Yes. In a minority of people, thromboembolic material does not resolve completely and may contribute to the development of chronic thromboembolic disease and chronic thromboembolic pulmonary hypertension.

Is pulmonary arterial hypertension always hereditary?
No. It may be idiopathic, heritable, associated with medications or toxins, or associated with conditions such as connective tissue diseases, congenital heart defects, portal hypertension, HIV infection and schistosomiasis.

Can pulmonary hypertension have more than one cause?
Yes. The same person may have several conditions contributing to increased pulmonary pressure. In complex cases, classification is based on the mechanism considered predominant after a comprehensive assessment.

References
  1. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal. 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237.
  2. Kovacs G, Bartolome S, Denton CP, et al. Definition, classification and diagnosis of pulmonary hypertension. European Respiratory Journal. 2024;64(4):2401324. doi:10.1183/13993003.01324-2024.
  3. Maron BA, Bortman G, De Marco T, et al. Pulmonary hypertension associated with left heart disease. European Respiratory Journal. 2024;64(4):2401344. doi:10.1183/13993003.01344-2024.
  4. Shlobin OA, Adir Y, Barberà JA, et al. Pulmonary hypertension associated with lung diseases. European Respiratory Journal. 2024;64(4):2401200. doi:10.1183/13993003.01200-2024.
  5. Kim NH, D'Armini AM, Delcroix M, et al. Chronic thromboembolic pulmonary disease. European Respiratory Journal. 2024;64(4):2401294. doi:10.1183/13993003.01294-2024.
  6. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal. 2019;53(1):1801913. doi:10.1183/13993003.01913-2018.
  7. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respiratory Medicine. 2016;4(4):306-322. doi:10.1016/S2213-2600(15)00543-3.
  8. Montani D, Günther S, Dorfmüller P, et al. Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases. 2013;8:97. doi:10.1186/1750-1172-8-97.
  9. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-387. doi:10.1378/chest.09-1140.
  10. Humbert M, Galiè N, Rubin LJ, Simonneau G, McLaughlin VV. The Seventh World Symposium on Pulmonary Hypertension: our journey to Barcelona. European Respiratory Journal. 2024;64(4):2401222. doi:10.1183/13993003.01222-2024.

Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.

Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.